Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1100 of 3499 entries
View as:

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00019721 Org: User:
Start: 04/30/99 End: 06/30/03 Due: 06/30/04

Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00096590 Org: User:
Start: 11/30/04 End: - Due: -

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01305213 Org: User:
Start: 03/21/11 End: 11/03/16 Due: 11/03/17

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01711541 Org: User:
Start: 10/22/12 End: 05/15/23 Due: 05/15/24

Monoclonal Antibody Therapy in Treating Patients With Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00019227 Org: User:
Start: 10/31/96 End: 07/31/06 Due: 07/31/07

Rare Tumors and Cancer Predisposition in Individuals and Families

Phase: N/A Priority: Normal
NCT ID: NCT05350761 Org: User:
Start: 03/10/23 End: 12/31/35 Due: 12/31/36

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05104736 Org: User:
Start: 04/06/22 End: 06/30/25 Due: 06/30/26

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04458922 Org: User:
Start: 10/05/20 End: 12/13/25 Due: 12/13/26

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04541017 Org: User:
Start: 04/06/21 End: 10/24/24 Due: 10/24/25

Cigarette Smoking and Oral Microbiota

Phase: N/A Priority: Normal
NCT ID: NCT01862809 Org: User:
Start: 05/23/13 End: 06/26/20 Due: 06/26/21

BRCA Mutations in Latinas

Phase: N/A Priority: Normal
NCT ID: NCT01251900 Org: User:
Start: 07/07/11 End: - Due: -

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05554406 Org: User:
Start: 09/25/24 End: 03/31/27 Due: 03/31/28

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01875601 Org: User:
Start: 06/11/13 End: 09/08/15 Due: 09/08/16

Tipifarnib in Treating Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00005845 Org: User:
Start: 06/30/02 End: - Due: -

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00936975 Org: User:
Start: 09/30/09 End: 12/31/14 Due: 12/31/15

Esophageal Cancer in Northeastern Iran

Phase: N/A Priority: Normal
NCT ID: NCT00450788 Org: User:
Start: 03/15/07 End: - Due: -

AZD2171 to Treat Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00436956 Org: User:
Start: 10/16/06 End: 02/05/14 Due: 02/05/15

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00064246 Org: User:
Start: 07/31/03 End: - Due: -

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Phase: N/A Priority: Normal
NCT ID: NCT06860594 Org: User:
Start: 03/01/26 End: 06/30/27 Due: 06/30/28

Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy

Phase: N/A Priority: Normal
NCT ID: NCT00001813 Org: User:
Start: 05/10/99 End: - Due: -

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT05436418 Org: User:
Start: 11/18/22 End: 07/02/27 Due: 07/02/28

Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01313442 Org: User:
Start: 03/02/11 End: - Due: -

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT01087294 Org: User:
Start: 08/04/10 End: 04/02/24 Due: 04/02/25

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Phase: N/A Priority: Normal
NCT ID: NCT01247597 Org: User:
Start: 02/13/11 End: - Due: -

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03922724 Org: User:
Start: 04/18/19 End: 10/31/30 Due: 10/31/31